Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 13 12 2022
medline: 19 1 2023
entrez: 12 12 2022
Statut: ppublish

Résumé

Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. To characterize the outbreak of monkeypox in Montréal, the first large outbreak in North America. Epidemiologic and laboratory surveillance data and a phylogenomic analysis were used to describe and place the outbreak in a global context. Montréal, Canada. Probable or confirmed cases of monkeypox. Epidemiologic, clinical, and demographic data were aggregated. Whole-genome sequencing and phylogenetic analysis were performed for a set of outbreak sequences. The public health response and its evolution are described. Up to 18 October 2022, a total of 402 cases of monkeypox were reported mostly among men who have sex with men (MSM), most of which were suspected to be acquired through sexual contact. All monkeypox genomes nested within the B.1 lineage. Montréal Public Health worked closely with the affected communities to control the outbreak, becoming the first jurisdiction to offer 1 dose of the Modified Vaccinia Ankara-Bavarian Nordic vaccine as preexposure prophylaxis (PrEP) to those at risk in early June 2022. Two peaks of cases were seen in early June and July (43 and 44 cases per week, respectively) followed by a decline toward near resolution of the outbreak in October. Reasons for the biphasic peak are not fully elucidated but may represent the tempo of vaccination and/or several factors related to transmission dynamics and case ascertainment. Clinical data are self-reported. Limited divergence among sequences limited genomic epidemiologic conclusions. A large outbreak of monkeypox occurred in Montréal, primarily among MSM. Successful control of the outbreak rested on early and sustained engagement with the affected communities and rapid offer of PrEP vaccination to at-risk persons. None.

Sections du résumé

BACKGROUND
Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas.
OBJECTIVE
To characterize the outbreak of monkeypox in Montréal, the first large outbreak in North America.
DESIGN
Epidemiologic and laboratory surveillance data and a phylogenomic analysis were used to describe and place the outbreak in a global context.
SETTING
Montréal, Canada.
PATIENTS
Probable or confirmed cases of monkeypox.
MEASUREMENTS
Epidemiologic, clinical, and demographic data were aggregated. Whole-genome sequencing and phylogenetic analysis were performed for a set of outbreak sequences. The public health response and its evolution are described.
RESULTS
Up to 18 October 2022, a total of 402 cases of monkeypox were reported mostly among men who have sex with men (MSM), most of which were suspected to be acquired through sexual contact. All monkeypox genomes nested within the B.1 lineage. Montréal Public Health worked closely with the affected communities to control the outbreak, becoming the first jurisdiction to offer 1 dose of the Modified Vaccinia Ankara-Bavarian Nordic vaccine as preexposure prophylaxis (PrEP) to those at risk in early June 2022. Two peaks of cases were seen in early June and July (43 and 44 cases per week, respectively) followed by a decline toward near resolution of the outbreak in October. Reasons for the biphasic peak are not fully elucidated but may represent the tempo of vaccination and/or several factors related to transmission dynamics and case ascertainment.
LIMITATIONS
Clinical data are self-reported. Limited divergence among sequences limited genomic epidemiologic conclusions.
CONCLUSION
A large outbreak of monkeypox occurred in Montréal, primarily among MSM. Successful control of the outbreak rested on early and sustained engagement with the affected communities and rapid offer of PrEP vaccination to at-risk persons.
PRIMARY FUNDING SOURCE
None.

Identifiants

pubmed: 36508736
doi: 10.7326/M22-2699
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-76

Auteurs

Luke B Harrison (LB)

Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada (L.B.H.).

Geneviève Bergeron (G)

Direction régionale de santé publique de Montréal, Montréal, Québec, Canada (G.B.).

Geneviève Cadieux (G)

Direction régionale de santé publique de Montréal and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada (G.C.).

Hugues Charest (H)

Laboratoire de santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, and Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada (H.C., J.F.).

Judith Fafard (J)

Laboratoire de santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, and Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada (H.C., J.F.).

Inès Levade (I)

Laboratoire de Santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, Québec, Canada (I.L.).

Antoine Cloutier Blais (AC)

Clinique l'Agora, Montréal, Québec, Canada (A.C.B., E.H.).

Emmanuelle Huchet (E)

Clinique l'Agora, Montréal, Québec, Canada (A.C.B., E.H.).

Benoît Trottier (B)

Clinique Médicale du Quartier Latin, Montréal, Québec, Canada (B.T., D.V.).

Dragos Vlad (D)

Clinique Médicale du Quartier Latin, Montréal, Québec, Canada (B.T., D.V.).

Jason Szabo (J)

Clinique Médicale l'Actuel, Montréal, Québec, Canada (J.S., R.T.).

Réjean Thomas (R)

Clinique Médicale l'Actuel, Montréal, Québec, Canada (J.S., R.T.).

Sébastien Poulin (S)

Clinique I.D., St-Jérôme, Québec, Canada (S.P.).

Christina Greenaway (C)

Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, and J.D. MacLean Centre for Tropical Diseases at McGill University, Montréal, Québec, Canada (C.G.).

Gerasimos J Zaharatos (GJ)

Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, Montréal, Québec, Canada (G.J.Z., M.O.).

Matthew Oughton (M)

Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, Montréal, Québec, Canada (G.J.Z., M.O.).

Arpita Chakravarti (A)

Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada (A.C.).

Robert Pilarski (R)

Clinique Médicale La Licorne, Montréal, Québec, Canada (R.P.).

Andrew Bui-Nguyen (A)

Clinique Quorum, Montréal, Québec, Canada (A.B., K.B.).

Khadija Benomar (K)

Clinique Quorum, Montréal, Québec, Canada (A.B., K.B.).

Michael D Libman (MD)

Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, J.D. MacLean Centre for Tropical Diseases at McGill University, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.D.L., S.B.).

Donald C Vinh (DC)

Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (D.C.V.).

Ana T Duggan (AT)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada (A.T.D.).

Morag Graham (M)

National Microbiology Laboratory, Public Health Agency of Canada, and Department of Medical Microbiology & Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada (M.G.).

Marina B Klein (MB)

Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.B.K.).

Sapha Barkati (S)

Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, J.D. MacLean Centre for Tropical Diseases at McGill University, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.D.L., S.B.).

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH